Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cellectis S.A. ADR (NQ: CLLS )

2.560 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,080
Open 2.520
Bid (Size) 2.500 (51)
Ask (Size) 2.560 (1)
Prev. Close 2.560
Today's Range 2.500 - 2.560
52wk Range 0.9628 - 3.773
Shares Outstanding 45,484,310
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CLLS Stock Earnings: Cellectis Misses EPS, Misses Revenue for Q4 2023
CLLS stock results show that Cellectis missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
From Cellectis Inc.
Via GlobeNewswire

Performance

YTD
-16.61%
-16.61%
1 Month
+0.79%
+0.79%
3 Month
-14.67%
-14.67%
6 Month
+152.17%
+152.17%
1 Year
+31.28%
+31.28%

More News

Read More
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
From Cellectis Inc.
Via GlobeNewswire
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
From Cellectis Inc.
Via GlobeNewswire
Earnings Scheduled For November 6, 2023
Via Benzinga
Earnings Preview: Cellectis
Via Benzinga
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
From Cellectis Inc.
Via GlobeNewswire
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis’ Shareholders Meeting to be Held on December 22, 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
From Cellectis Inc.
Via GlobeNewswire
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Roku Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
From Cellectis Inc.
Via GlobeNewswire
Dow Gains Over 100 Points; Fed Leaves Interest Rates Unchanged
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Is Cancer Player Cellectis Stock Trading Over 100% Higher Today?
Via Benzinga
Nasdaq Surges Over 100 Points Ahead Of Fed Decision; WeWork Shares Plunge
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
US Stocks Mixed; Private Sector Payrolls Increase Less Than Expected
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Why Is WeWork (WE) Stock Down 38% Today?
Via InvestorPlace
Topics Bankruptcy
Exposures Financial Legal
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.